Physician profile
Danielle Augugliaro
NPI 1245713304
$871.40
in general payments reported to CMS, 2019-2025
10 companies · $55.69 in 2025
The $55.69 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.51 · 2021: $220 · 2022: $240 · 2023: $67.84 · 2024: $261 · 2025: $55.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $370.49 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $271.87 | 2020-2024 | Lifevest |
| Abbvie INC. | $53.71 | 2021 | |
| Pfizer INC. | $36.98 | 2024 | |
| Kestra Medical Technology Services, INC. | $35.43 | 2025 | Assure Wcd |
| Indivior INC. | $23.53 | 2024 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $21.91 | 2022 | |
| Melinta Therapeutics, LLC | $21.78 | 2024 | Orbactiv, Kimyrsa, Rezzayo |
| E.R. Squibb & Sons, L.L.C. | $20.26 | 2025 | Eliquis |
| Amgen INC. | $15.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Augugliaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.